Bookbuilding IPO | ₹2,180 Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Symbiotec Pharmalab Ltd. on March 25, 2026. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Symbiotec Pharmalab Ltd. IPO is a Book Build Issue of ₹2,180.00 crores consisting of a fresh issue of shares worth Rs ₹150.00 crores and an offer for sale (OFS) of ₹2,030.00 crores.
The equity shares are proposed to be listed on NSE and BSE. JM Financial Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Symbiotec Pharmalab IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹2 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | [.] shares (agg. up to ₹2,180 Cr) |
| Fresh Issue | [.] shares (agg. up to ₹150 Cr) |
| Offer for Sale | [.] shares of ₹2 (agg. up to ₹2,030 Cr) |
| Share Holding Pre Issue | 6,16,81,496 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Dec 19, 2025 |
| SEBI/Exchange approval received | Wed, Mar 25, 2026 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35.00% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions.
It emphasizes research-driven manufacturing, quality compliance, and sustainable processes. Symbiotec Pharmalab Ltd. supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards.
With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations.
As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres.
Competitive Strengths:
Symbiotec Pharmalab Ltd.'s revenue increased by 5% and profit after tax (PAT) dropped by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,598.34 | 1,579.65 | 1,294.79 | 989.99 |
| Total Income | 205.81 | 755.98 | 723.33 | 572.97 |
| Profit After Tax | 29.92 | 96.79 | 100.06 | 23.49 |
| EBITDA | 60.61 | 206.11 | 177.04 | 74.25 |
| NET Worth | 854.43 | 821.15 | 720.68 | 621.17 |
| Reserves and Surplus | 835.26 | 803.77 | 703.91 | 610.50 |
| Total Borrowing | 519.12 | 540.92 | 247.21 | 217.88 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| 2 | General corporate purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 12.66% |
| ROCE | 11.80% |
| RoNW | 11.79% |
| PAT Margin | 12.80% |
| EBITDA Margin | 27.26% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 34.47% |
Symbiotec Pharmalab IPO is a main-board IPO of 0 equity shares of the face value of ₹2 aggregating up to ₹2,180 Crores. The issue is priced at To be declared. The minimum order quantity is .
The Symbiotec Pharmalab IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Symbiotec Pharmalab IPO using UPI as a payment gateway. Zerodha customers can apply in Symbiotec Pharmalab IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Symbiotec Pharmalab IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Symbiotec Pharmalab IPO dates are not announced. Please check back again after some time.
Symbiotec Pharmalab IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Symbiotec Pharmalab IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Symbiotec Pharmalab IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Symbiotec Pharmalab IPO allotment status.
The Symbiotec Pharmalab IPO listing date is not yet announced. The tentative date of listing is .
